Home page > Europe and Health | Health, wealth and equity | Health friendly research and innovation | EU Funding and programmes | Irish Presidency priorities


Please find all related articles below.

Vote on Medical Devices once more postponed

The European Parliament’s ENVI Committee vote on the proposals for Regulations on Medical Devices and InVitro Medical Devices has been postponed for the second time. There are rising concerns by health stakeholders regarding the speed of the process, as ongoing delays undermine public trust in the EU’s ability to create legislation that will adequately protect patients. On Wednesday 18 September, the ENVI committee postponed the vote on the Medical Devices Regulations for the (...)

[Update] General Data Protection Regulation

Originally scheduled to take place in April, the European Parliament’s Committee on Civil Liberties, Justice and Home Affairs (LIBE) is now set to vote on the General Data Protection Regulation in October. This article provides a brief update on the events which have hindered the file’s progress and the current state of legislative deliberation. Progress to date Following the publication of the European Commission’s proposals to revise and update the EU’s data (...)

WHO consultation on climate change and health research priorities (July 19th)

WHO has launched the "Research priority setting exercise: Health and Climate Change Agenda 2015-2025" survey - a unique opportunity to contribute to the debate on climate change and health research priorities: air quality and respiratory disease, cardiovascular diseases and stroke, heat- and weather-related morbidity, mental health, food vector and water borne diseases. The deadline of this survey is July 19th (Friday). Summary of the research Climate change is now widely considered to (...)

Reindustrialising Europe to promote competitiveness and sustainability - But does it promote health?

Currently, the Industry, Research and Energy (ITRE) Committee of the European Parliament is working on its own initiative report on re-industrialising Europe to promote competitiveness and sustainability. The Parliament’s Environment, Public Health and Food Safety (ENVI) Committee prepared an opinion drafted by Tadausz Cymanski MEP (EPP, Poland) and amendments to this draft opinion were tabled and will be voted on on 19 June. The question is now whether the ENVI Committee has taken (...)

Open letter on trilogue negotiations on EU’s Framework Programme for Research and Innovation (2014-2020) Horizon 2020

EPHA, together with 12 other organisations, signed an open letter urging trialogue decision makers to, though the adoption of appropriate licensing conditions, ensure global access to lifesaving medical innovations developed under the [EU Framework Programme for research and Innovation Horizon 2020. >http://ec.europa.eu/research/horizo...] In this letter, the signatory organisations stated that " any publicly funded medical product -be it a drug, vaccine or medical diagnostic- should be (...)

[Joint Press Statement] Access to medicines in Europe: The EU cannot save banks while sacrificing people’s health

Brussels, 17 May – In a seminar hosted yesterday by the Group of the Progressive Alliance of Socialists & Democrats (S&D) in the European Parliament and the Member of the European Parliament (MEP) Alejandro Cercas (S&D, Spain), six MEPs from various political groups (1) along with representatives of governments, leading academics, researches and public health organisations (2) met to raise awareness about one of the most alarming issues that European healthcare systems (...)

[EPHA Briefing] Access to Medicines in Europe in Times of Austerity

When discussing the topic of access to medicines in the context of the economic crisis we have to consider three determinants: affordability and availability, in terms of access to medicines, and innovation in terms of developing new methods of assuring best possible health outcomes. AFFORDABILILTY Usually, health expenditures are mostly covered by public funding and supplemented by private spending. The economic crisis has forced public expending to be cut making patient co-payment (...)

[Seminar report] Can EU Citizens Afford Their Medicines?

This high level meeting revolved around various political processes linked to the economic crisis. Some of the topics discussed include implementation of the Europe 2020 strategy, as well as pharmaceutical legislation for ensuring that people living in Europe have access to a wide range of quality and affordable medicines. The meeting hosted by Mr Alejandro Cercas, MEP (Spain,S&D) and by the Socialists and Democrats in the European Parliament (S&D Group) served to assess the impact (...)

Public consultation on Declaration of Helsinki on medical research involving human subjects

A two-month public consultation (15 April to 15 June 2013) on the World Medical Association’s Declaration of Helsinki on medical research involving human subjects has been launched by the World Medical Association. A revised version of the Declaration is available on the WMA website. This consultation is of particular interest in the context of the ongoing revision of the Clinical Trials legislation. Please click here for detailed information on the consultation process The (...)

Clinical trials: Exploring the limits of transparency

Glenis Willmott MEP (S&D, UK) took the initiative to bring together experts to discuss the extent to which more transparency could be workable in non-commercial clinical trials. The debate, which took place in the European Parliament on 10 April, served to present the key arguments for and against increased transparency in the context of administrative and data reporting requirements for academic researchers and patient safety. EPHA’s Position on Clinical Trials urges political (...)